Home Healthcare Gene Therapy Market
gene therapy market

Gene Therapy Market by Background, Biology, Treatment Approaches, Gene Therapy Programs, Potential Catalysts, Public and Private Gene Therapy Companies, Key Partnerships in the Field, Challenges in Gene therapy, Commercial Opportunities, Focus on Gene Therapy, Gene Editing and Novel Technologies, Future Leaders & Gene Therapy Outlook & by Regions, Forecast by 2021

  • Published Date: Jan 2018
  • Pages: 100
  • Format: PDF
  • Report ID: PM1084
  • Base Year: 2016
  • Historical Data: 2015

The major segments which has been investigated in the global market from 2016-2021 are:

  • Market Analysis by Marketed Gene Therapies
  • Market Analysis by Companies
  • Market Analysis by Indications

The Marketed Therapies undertaken in forecast from 2016-2021 are:

  • Rexin-G (Epeius Biotechnologies Corporation)
  • Gendicine (SiBiono GeneTech Co., Ltd)
  • Neovasculgen [Human Stem Cells Institute (HSCI))
  • Glybera (UniQure Biopharma B.V.)
  • KYMRIAH (Novartis)
  • YESCARTA (Kite Pharmaceuticals)
  • LUXTURNA (Spark Therapeutics)
  • STRIMVELIS (GlaxoSmithKline)

The Major Indications in Gene Therapy are:

  • Cancer
  • Neurodegenerative Disorders
  • Lysosomal Storage Disorders (LSDs)
  • Ocular Diseases
  • Muscle Disorders
  • Anemia
  • Hemophilia
  • Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency

 Leading Companies investigated in the Report are

  • Novartis Pharmaceuticals Corporation
  • Kite Pharma, Incorporated
  • Spark Therapeutics, Inc
  • GlaxoSmithKline
  • Adaptimmune
  • Bluebird bio
  • Celgene
  • Shanghai Sunway Biotech
  • Shenzhen SiBiono GeneTech
  • SynerGene Therapeutics
  • Other Companies
Polaris Market Research
Gene Therapy Market Size, Share - Global Industry Growth Report 2021